NKGen Biotech, Inc. “A Phase 1/2a Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of SNK01 in Participants with Moderate Alzheimer’s Disease (Study SNK01-AD01)”



The primary purpose of this research is to evaluate the safety of NK cell therapy when given alone. A secondary objective is to evaluate any preliminary efficacy by the change in cognitive assessment scores.

Enrollment Form

This study is currently enrolling.